Sub-analyses of currently ongoing clinical trials investigating the efficacy of FGFR2 or pan-FGFR inhibitors in solid tumors will show the impact of heterogeneity of FGFR2-amplified tumor cell clones on treatment response or failure. This evidence concerns the gene FGFR2 and neoplasm.